Clinical Research

Found 101,366 articles

• Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in Advanced NSCLC at WCLC 2017

  10/17/2017

  This is the first data published using amplicon-based technology to detect ALK and ROS1 fusions.

• Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with MRIdian MR-Guided Radiation Therapy

  10/17/2017

  ViewRay announced today outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

• Anpac Bio Surpasses 50,000 Case Study Milestone

  10/17/2017

  Dr. Chris Yu, CEO of international life sciences corporation Anpac Bio, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

• Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

  10/17/2017

  Invitae is presenting data showing genetic sequencing and copy number variant (CNV) detection performed together using expert-curated panels offers better diagnosis rates over sequencing alone in patients with neuromuscular disorders and childhood epilepsy.

• UZ Leuven Treats First Patient in Europe on Varian Halcyon Cancer Treatment System

  10/17/2017

  Variantoday announced an 80-year-old male with head & neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven in Belgium.

• Significant Advance in Breast Cancer Care – Cohera Medical Drain-Free Mastectomy Trial Reaches Full Enrollment

  10/17/2017

  11 breast centers in the UK and Germany complete enrollment of a clinical study comparing mastectomy flap closure using TissuGlu without surgical drains vs. standard of care with drain.

• Southern Spine Announces "Clinical and Biomechanical Advantages of Interspinous Process Fixation: A Review"

  10/17/2017

  Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced today the release of a current literature review on the "Clinical and Biomechanical Advantages of Interspinous Process Fixation."

• Children’s Hospital Los Angeles Release: A Liquid Biopsy For Retinoblastoma Developed By Children’s Hospital Los Angeles And Keck Medicine Of USC

  10/17/2017

  Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed using a biopsy, retinoblastoma tumors cannot be directly biopsied.

• Prime Therapeutics Study Finds A Diabetes Drugs Value Based Insurance Design Improves Adherence, Doesn't Lower Total Cost Of Care

  10/16/2017

• Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome

  10/16/2017

  New data from the global IN-FOCUS study were presented at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.

• Takeda Release: New Post-Hoc Analyses Report Early Symptomatic Improvement In Moderately To Severely Active Ulcerative Colitis Or Crohn's Disease Patients Taking Entyvio (Vedolizumab), Particularly In Biologic-Naïve Patients

  10/16/2017

  Takeda today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), particularly in biologic-naïve patients for whom other therapies have not worked well enough.

• Creative Medical Technology Holdings Expands Stem Cell Therapeutic Platform By Entry Into Field Of Stroke And Neurodegeneration

  10/16/2017

  Creative Medical Technology Holdings announced today filing of a patent application using a combination of an FDA approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke.

• Enzyvant Initiates Farber Disease Natural History Study

  10/16/2017

  Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced the initiation of the Farber Disease Natural History Study.

• A*STAR Release: Scientists Uncover A New Layer Of Complexity Beyond The Human Genome

  10/16/2017

  Singaporean researchers have made significant inroads in the study of Ribonucleic Acid (RNA) editing.

• Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases

  10/16/2017

  Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.

• Leader of Johnson & Johnson 3D Printing Center of Excellence Outlines Advantages of Customized Knee Implants

  10/16/2017

  ConforMIS has obtained additional positive clinical data regarding the performance of its customized partial knee replacement implants.

• PacBio's Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes

  10/16/2017

  A series of publications and initiatives from the genomics community demonstrates the rapid adoption of Single Molecule, Real-Time Sequencing for discovering structural variants throughout the human genome

• Soft Suit Exoskeleton Technology Begins Next Phase Of Testing In Pre-Clinical Study

  10/16/2017

  ReWalk today announced that the soft exosuit technology currently in development has entered the next phase of testing and verification in collaboration with researchers at Harvard University's Wyss Institute for Biologically Inspired Engineering.

• ReWalk Completes Critical Design Review Processes Of Restore System For Move To Clinical Studies

  10/16/2017

  ReWalk announced today completion of all internal processes to initiate clinical studies and the initial production of its "soft suit" exoskeleton design for stroke patients.

• ChemPass And LifeArc Report Positive Results In The Validation of ChemPass Technology In Medicinal Chemistry Programs

  10/16/2017

  ChemPass announced today that they have successfully completed the first phase of their evaluation of ChemPass' technology for its ability to support LifeArc's medicinal chemistry programs.